Cftr Trikafta denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Trikafta on Medical-Necessity Grounds

A medical-necessity denial does not mean Aetna disputes that cystic fibrosis is serious—it means the reviewer concluded that the submitted documentation did not satisfy each specific criterion in Aetna's current coverage policy for this drug. Common shortfalls include: the genetic mutation report was missing or used ambiguous nomenclature; the chart lacked a recent pulmonary function assessment; or the prescriber's letter described the condition in general terms without mapping to Aetna's policy language point-by-point.

These denials are highly reversible with a well-organized appeal that fills each documentation gap.

## Your Federal Appeal Rights

• Internal appeal: You are entitled to a Level 1 internal review. File within the deadline on your denial notice. Request the written criteria Aetna used and the reviewing clinician's specialty.
• External review (ACA §2719 / ERISA §503): After the internal appeal, you have the right to an independent external reviewer bound by objective medical-evidence standards, not Aetna's internal policy alone. The external-review window is generally 4 months from the final denial.
• Expedited review: Available if standard timelines would seriously jeopardize your health or ability to regain maximum function.

## Documentation to Gather

1. Confirmed CF diagnosis: Sweat chloride test results and/or genetic mutation analysis using nomenclature that aligns with the terminology in Aetna's policy and the FDA label. 2. Current pulmonary function data: Recent spirometry results with trend data showing disease course, interpreted by the treating CF specialist. 3. Prior treatment history: Documentation of all prior CF therapies with dates, dosing information from the prescriber, and documented clinical response or failure. 4. Prescriber medical-necessity letter: Should address every criterion in Aetna's published policy by name, citing specific chart dates and findings—not general statements about the disease. 5. Aetna's policy document: Download the current version directly from Aetna's website. Verify the effective date and confirm you are responding to the operative criteria.

## Criteria-Mapping Structure

Build a point-by-point table in your appeal letter:

| Aetna Policy Criterion (copy verbatim) | Chart Evidence Supporting It | |---|---| | Confirmed CF genotype eligible under policy | Genetic report dated __ | | Current clinical status assessment | Spirometry + clinic notes dated __ | | Prescriber is CF specialist or pulmonologist | Treating MD credentials | | No contraindication per policy | Prescriber attestation in medical-necessity letter |

Address any criterion Aetna cited in the denial notice directly and by name. If a document was missing from the original submission, include it now and note that it is newly submitted evidence.